ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag policy vaccine art genetics genomics

Illustration of scientists
Opinion: How Large International Collaborations Have Fared in the Pandemic
Sadye Paez, Giulio Formenti, and Erich D. Jarvis | May 2, 2022 | 5 min read
COVID-19 has challenged the progress of Big Science. Here are the lessons learned.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Genome Investigator Craig Venter Reflects On Turbulent Past And Future Ambitions
Karen Young Kreeger | Jul 23, 1995 | 8 min read
And Future Ambitions Editor's Note: For the past four years, former National Institutes of Health researcher J. Craig Venter has been a major figure in the turbulent debates and scientific discoveries surrounding the study of genes and genomes. Events heated up in 1991, when NIH attempted to patent gene fragments, which were isolated using Venter's expressed sequence tag (EST)/complementary DNA (cDNA) approach for discovering human genes (M.A. Adams et al., Science, 252:1651-6, 1991). NIH's mo
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Privatizing the Human Genome?
Paul Smaglik | Jun 7, 1998 | 10 min read
Principals behind joint-venture proposal and public effort seek to define relationships A private effort to sequence the human genome four years ahead of the Human Genome Project's 2005 goal could either compete directly with the federal project or meld seamlessly with it. Before any relationship between the two efforts becomes formalized, scientists and federal officials involved with the Human Genome Project must determine whether the private approach will work, who will own the data, how qu
Vaccines: Victims of Their Own Success?
Ricki Lewis | Jul 18, 2004 | 10+ min read
Perhaps in no area is the divide between the developed and developing worlds as striking as it is for vaccines: While healthcare consumers in economically advantaged nations worry about risk, in developing nations compelling need forces a focus on potential benefit. "People in the United States want a quick solution, not prevention, so they prefer drugs to vaccines. Elsewhere, people are afraid of drugs and side effects, and prefer vaccines," says Shan Lu, a primary-care physician who has worked
Will Genomics Spoil Gene Ownership?
Douglas Steinberg | Sep 3, 2000 | 8 min read
Consider a scenario for the year 2002: Using commercially available software, bioprospector "Craig Collins" spends a day scavenging the Human Genome Project (HGP) database for the alternatively spliced genes prized by Wall Street. He enters the sequences of several candidate genes into a software package that prints out the likely functions of their protein products. One protein looks like it could be pharmaceutical paydirt, so he isolates the corresponding cDNA, inserts it into a vector, then
Looking Back At Jenner, Vaccine Developers Prepare For 21st Century
Kathryn Brown | Apr 1, 1996 | 8 min read
This year marks the 200th anniversary of the first vaccine, which was developed against smallpox. As vaccine researchers launch a new century of challenging disease science, they might find inspiration in the simple beginnings of Edward Jenner's discovery. 
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Scientific Enterprise At Critical Juncture, Say Panelists, Researchers
Steven Benowitz | Oct 13, 1996 | 10+ min read
MISCONDUCT POLICY: University of Illinois' C.K. Gunsalus cites problems of oversight in academia. Is science in crisis? Scientists, historians, administrators, and others have debated this issue over the last few decades. The controversial topic was the impetus for a September 19 conference at George Washington University (GWU). Panelists at the day-long symposium, titled "Science in Crisis at the Millennium," think something has gone awry. Keith Yamamoto, University of California, San Franc

Run a Search

ADVERTISEMENT